USE OF MODERN PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS IN REAL CLINICAL PRACTICE
This study examined the principles of pharmacotherapy for the selection of GBI (genetically engineered biological preparations) for patients with severe RA (rheumatoid arthritis), given the stage, degree of activity, rate of disease progression, and contraindications. The effectiveness of the treatment with various GBI in combination with basic anti-inflammatory drugs and comorbid diseases was assessed. The features of the course of RA, complications, comorbidity, and specificity of the drug were taken into account. Regular monitoring of drug tolerance was carried out, which allowed to reduce the risk of undesirable drug reactions. The study included patients with a reliable diagnosis of RA (ACR / EULAR criteria of 2010) who underwent routine treatment in the rheumatology department of the Novgorod Regional Clinical Hospital GOBUZ from November 2019 to March 2020 to obtain a GBI due to the severe course of RA (III art. activity at the time of initiation of HIBP therapy) with different duration of the disease. The study allows the use of modern treatment regimens for GBI in conjunction with BPD or as monotherapy, which makes it possible in most cases to reduce the high activity of RA in patients with severe course of the disease in real clinical practice. For a more accurate assessment of the effectiveness of combination therapy, improving the results of treatment of GBI, Further studies are necessary.